Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

sNDA for Darolutamide Plus ADT in mHSPC Submitted for FDA Review

September 26th 2024

A supplemental new drug application seeking to expand the indication for darolutamide plus ADT in mHSPC has been submitted to the FDA.

Dr Saad on the Efficacy and Safety of Darolutamide Plus ADT in mHSPC

September 25th 2024

Fred Saad, CQ, MD, FRCS, FCAHS, discusses efficacy findings from the ARANOTE trial in patients with metastatic hormone-sensitive prostate cancer.

Dr Morgans on Recent Adjustments to Medicare Part D to Improve Treatment Access in Prostate Cancer

September 24th 2024

Alicia Morgans, MD, MPH, discusses recent adjustments to Medicare Part D rules, emphasizing their positive impact on out-of-pocket costs for patients with prostate cancer.

Dr Berchuck on Detecting PSMA Expression With a Novel Epigenomic Liquid Biopsy in mCRPC

September 24th 2024

Jacob E. Berchuck, MD, discusses the use of a novel epigenomic liquid biopsy platform to noninvasively detect PSMA expression in mCRPC.

Rintatolimod Plus Durvalumab Shows Early Disease Control in Late-Stage Pancreatic Cancer

September 19th 2024

Rintatolimod plus durvalumab led to stable disease at 6 months in 2 of 3 patients with late-stage pancreatic cancer treated at the first dose level.

Dr Morgans on Previously Reported Data From the ARAMIS Trial in nmCRPC

September 18th 2024

Alicia Morgans, MD, MPH, discusses prior data and follow-up analysis of the ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Darolutamide Plus ADT Improves rPFS in mHSPC

September 16th 2024

Darolutamide plus ADT shows PFS benefit without docetaxel in metastatic hormone-sensitive prostate cancer.

Addition of Radium-223 to Enzalutamide Significantly Improves rPFS and OS in mCRPC

September 14th 2024

Radium-223 plus enzalutamide yielded significant rPFS and OS benefits vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer.

Dr D’Amico on the Nuances of a Low Gleason Score in Localized Prostate Cancer

September 10th 2024

Anthony V. D'Amico, MD, PhD, discusses Gleason score interpretation in the management of localized prostate cancer.

The OncFive: Top Oncology Articles for the Week of 9/1

September 7th 2024

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

FDA Green Lights Companion Diagnostics for Olaparib Plus Abiraterone Acetate in BRCA+ mCRPC

September 3rd 2024

The FDA approved companion diagnostics for olaparib plus abiraterone in metastatic castration-resistant prostate cancer.

Dr Olivares on the Functional Advantages of Focal Therapy in Prostate Cancer

August 30th 2024

Ruben Olivares, MD, discusses the functional advantages of using focal therapy over localized radiation in prostate cancer.

ADT Plus Darolutamide Is Associated With Lower Rates of PSA Progression in nmCRPC

August 29th 2024

Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.

Dr Olivares on Considerations for Managing Prostate Cancer in the Community Setting

August 29th 2024

Ruben Olivares, MD, discusses considerations for managing prostate cancer in the community setting, particularly regarding early detection and screening.

Dr Guerra on the Implications of a Study on Prostate Cancer Screening in Diverse Populations

August 28th 2024

Carmen Guerra, MD, MSCE, FACP, discusses the implications of research into the rates of prostate cancer screening in a population of diverse men.

64Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PET Imaging in Prostate Cancer

August 27th 2024

The FDA has granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions.

Dr Townsend on the Future Analysis of Prostate Cancer Driver Mutations Using Neoplasm Tissue Samples

August 27th 2024

Jeffrey P. Townsend, PhD, discusses analysis of prostate cancer driver mutations using early neoplasm tissue samples.

Dr Dreicer on the Complexities of Prostate Cancer

August 23rd 2024

Robert Dreicer, MD, discusses his presentation from the 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.

Dr Morgans on Considerations for Treating nmCRPC in the Community Setting

August 22nd 2024

Alicia Morgans, MD, MPH, discusses considerations for oncologists treating patients with nonmetastatic castration-resistant prostate cancer in the community setting.

Olaparib Monotherapy Elicits Responses in HRR+ Prostate Cancer With High-Risk Biochemical Recurrence

August 22nd 2024

Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations.